ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Molecular and Clinicopathological Biomarkers Predicting Brain Metastasis in Triple-Negative Breast Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- CAR-T cell therapy: potential for paediatric brain tumours-an update.Journal of neuro-oncology · 2026Review
- Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases.Cancer research communications · 2026Article
- Screening of core targets for Di(2-ethylhexyl) Phthalate-related gastric cancer based on machine learning, molecular docking, and SHAP analysis.PLoS computational biology · 2026Article
- Review
- A Literature Review of Interleukins in the Development and Treatment of Breast Cancer.International journal of molecular sciences · 2026Review
- Development of a quadruple-conjugated carbon dot nanomodel for targeted glioma therapy.Communications chemistry · 2026Article
- Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors.ImmunoTargets and therapy · 2026Article
- Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models.Journal for immunotherapy of cancer · 2025Article
- CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer.NPJ precision oncology · 2025Article
- Tumor cells upregulate neurotransmitter GABA in the choroid plexus through STAT6-Bestrophin1 signaling, promoting leptomeningeal dissemination.Neuro-oncology · 2025Article
- Loss of IL13RA2 promotes metastatic tumor growth in triple-negative breast cancer via increased AKT and NF-κB signaling.Clinical & experimental metastasis · 2025Article
- Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop.The Journal of clinical investigation · 2025Article
- Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation.Journal for immunotherapy of cancer · 2025Article
- Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing.Neuro-oncology · 2025Article
- An intraepithelial ILC1-like natural killer cell subset produces IL-13.Frontiers in immunology · 2025Article
- Multi-Omics Insights into the Impact of MDH2 on Breast Cancer Progression: A Promising Druggable Target.Oncology research · 2025Article
- IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Protein Tyrosine Phosphatase 1B (PTP1B): A Comprehensive Review of Its Role in Pathogenesis of Human Diseases.International journal of molecular sciences · 2024Review
- Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe survival of women with brain metastases (BM) from breast cancer remains very poor, with over 80% dying within a year of their diagnosis. Here, we define the function of IL13Rα2 in outgrowth of breast cancer brain metastases (BCBM) EXPERIMENTAL
designWe performed IHC staining of IL13Rα2 in BCBM to define its prognostic value. Using inducible shRNAs in TNBC and HER2
resultsHigh IL13Rα2 expression in BCBM predicted worse survival after BM diagnoses. IL13Rα2 was essential for cancer-cell survival, promoting proliferation while repressing invasion. IL13Rα2 KD resulted in FAK downregulation, repression of cell cycle and proliferation mediators, and upregulation of Ephrin B1 signaling. Ephrin-B1 (i) promoted invasion of BC cells
conclusionsNon-genomic phenotypic adaptations at metastatic sites are critical to BM progression and patients' prognosis. This study opens the road to use IL13Rα2 targeting as a therapeutic strategy for BM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.